222 related articles for article (PubMed ID: 28694026)
1. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
2. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
3. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
Hodgins NO; Al-Jamal WT; Wang JT; Klippstein R; Costa PM; Sosabowski JK; Marshall JF; Maher J; Al-Jamal KT
J Control Release; 2017 Jun; 256():141-152. PubMed ID: 28432037
[TBL] [Abstract][Full Text] [Related]
4. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
5. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of amino-bisphosphonates on circulating γδ T cells.
Rossini M; Adami S; Viapiana O; Fracassi E; Ortolani R; Vella A; Zanotti R; Tripi G; Idolazzi L; Gatti D
Calcif Tissue Int; 2012 Dec; 91(6):395-9. PubMed ID: 23052225
[TBL] [Abstract][Full Text] [Related]
8. Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models.
Wang JT; Hodgins NO; Al-Jamal WT; Maher J; Sosabowski JK; Al-Jamal KT
Nanotheranostics; 2020; 4(2):71-82. PubMed ID: 32190534
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
10. Activation of γδ T cells by bisphosphonates.
Thompson K; Roelofs AJ; Jauhiainen M; Mönkkönen H; Mönkkönen J; Rogers MJ
Adv Exp Med Biol; 2010; 658():11-20. PubMed ID: 19950011
[TBL] [Abstract][Full Text] [Related]
11. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
Tanaka Y
Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
16. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
17. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
18. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
19. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]